NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics (Elafibranor, Ocaliva, Selonsertib, Cenicriviroc, Emricasan, and Other Therapeutics), By Diagnostics (Imaging Techniques, Diagnostic Tests, and Biopsy), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)-

Published In : Feb 2023
Code : CMI2279
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is highly competitive. This is attributed to the rise in demand for safe and effective NASH therapeutics and diagnostics, as a result, market players are focusing on launching novel products in the market.

Some of the key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market are Novartis AG, Allergan Plc., Viking Therapeutics, Merck & Co., Zydus Cadila, Novo Nordisk A/S, GENFIT SA, Gilead Sciences Inc., Galmed Pharmaceuticals, Madrigal Pharmaceuticals, and Intercept Pharmaceuticals Inc., among others.